Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Chimeric antigen receptor-T cell therapy - Alaya.bio

Next Previous
Drug Profile

Chimeric antigen receptor-T cell therapy - Alaya.bio

Alternative Names: CAR-T therapy - Ixaka; CELTIC-19; Chemically encapsulated Lentiviral vector for targeted In Vivo CAR T-cell therapy

Latest Information Update: 29 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator aratinga.bio
  • Developer Alaya.bio
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haematological malignancies
  • No development reported Cancer

Most Recent Events

  • 21 Jan 2025 Alaya.bio collaborates with Columbia University to advance research into CAR-T cell therapies
  • 28 Aug 2024 No recent reports of development identified for preclinical development in Cancer in United Kingdom (Parenteral)
  • 18 Jan 2024 Alaya.bio enters into a licensing and a sponsored research agreement with Memorial Sloan Kettering Cancer Center (MSK) to advance research into in situ CAR-T cell therapies

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top